Research programme: GABA-A modulating steroid receptor antagonists - Umecrine Cognition/CleveXel Pharma

Drug Profile

Research programme: GABA-A modulating steroid receptor antagonists - Umecrine Cognition/CleveXel Pharma

Alternative Names: CVXL-0060

Latest Information Update: 13 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Umecrine Cognition
  • Developer CleveXel Pharma; Umecrine Cognition
  • Class Small molecules
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatic encephalopathy

Most Recent Events

  • 23 Oct 2013 Umecrine Cognition & CleveXel Pharma agree to collaborate in the development of CVXL 0060 for hepatic encephalopathy
  • 23 Oct 2013 Early research in Hepatic encephalopathy in France (PO)
  • 23 Oct 2013 Early research in Hepatic encephalopathy in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top